These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 15649042)

  • 1. Major degradation product identified in several pharmaceutical formulations against the common cold.
    Marín A; Espada A; Vidal P; Barbas C
    Anal Chem; 2005 Jan; 77(2):471-7. PubMed ID: 15649042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Major degradation product identified in several pharmaceutical formulations against the common cold.
    Wong J; Wiseman L; Al-Mamoon S; Cooper T; Zhang LK; Chan TM
    Anal Chem; 2006 Nov; 78(22):7891-5. PubMed ID: 17105185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of LC/MS, GC/MS, and LC/NMR hyphenated techniques to identify a drug degradation product in pharmaceutical development.
    Pan C; Liu F; Ji Q; Wang W; Drinkwater D; Vivilecchia R
    J Pharm Biomed Anal; 2006 Feb; 40(3):581-90. PubMed ID: 16242883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug-excipient compatibility testing-Identification and characterization of degradation products of phenylephrine in several pharmaceutical formulations against the common cold.
    Douša M; Gibala P; Havlíček J; Plaček L; Tkadlecová M; Břicháč J
    J Pharm Biomed Anal; 2011 Jul; 55(5):949-56. PubMed ID: 21481557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LC/MS for the degradation profiling of cough-cold products under forced conditions.
    Marín A; Barbas C
    J Pharm Biomed Anal; 2004 Sep; 35(5):1035-45. PubMed ID: 15336351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isolation, identification and determination of the major degradation product in alprazolam tablets during their stability assay.
    Huidobro AL; Rupérez FJ; Barbas C
    J Pharm Biomed Anal; 2007 Jun; 44(2):404-13. PubMed ID: 17250986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification and characterization of degradation products of dicloxacillin in bulk drug and pharmaceutical dosage forms.
    Raj TJ; Bharati CH; Rao KR; Rao PS; Narayan GK; Parikh K
    J Pharm Biomed Anal; 2007 Mar; 43(4):1470-5. PubMed ID: 17125952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strategy for identification of leachables in packaged pharmaceutical liquid formulations.
    Pan C; Harmon F; Toscano K; Liu F; Vivilecchia R
    J Pharm Biomed Anal; 2008 Feb; 46(3):520-7. PubMed ID: 18180126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification, isolation and characterization of a new degradation product in sultamicillin drug substance.
    Kumar VJ; Gupta PB; Kumar KS; Ray UK; Sreenivasulu B; Kumar GS; Rao KR; Sharma HK; Mukkanti K
    J Pharm Biomed Anal; 2011 Feb; 54(3):582-7. PubMed ID: 20934824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of liquid chromatography-two-dimensional nuclear magnetic resonance spectroscopy using pre-concentration column trapping and liquid chromatography-mass spectrometry for the identification of degradation products in stressed commercial amlodipine maleate tablets.
    Murakami T; Fukutsu N; Kondo J; Kawasaki T; Kusu F
    J Chromatogr A; 2008 Feb; 1181(1-2):67-76. PubMed ID: 18191867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LC and LC-MS study of stress decomposition behaviour of isoniazid and establishment of validated stability-indicating assay method.
    Bhutani H; Singh S; Vir S; Bhutani KK; Kumar R; Chakraborti AK; Jindal KC
    J Pharm Biomed Anal; 2007 Mar; 43(4):1213-20. PubMed ID: 17118610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multidisciplinary approach to identify a degradation product in a pharmaceutical dosage form.
    Pan C; Guan J; Lin M
    J Pharm Biomed Anal; 2011 Mar; 54(4):855-9. PubMed ID: 21129882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and characterization of major degradation products of risperidone in bulk drug and pharmaceutical dosage forms.
    Tomar RS; Joseph TJ; Murthy AS; Yadav DV; Subbaiah G; Krishna Reddy KV
    J Pharm Biomed Anal; 2004 Sep; 36(1):231-5. PubMed ID: 15351071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of high-performance liquid chromatography hyphenated techniques for identification of degradation products of cefpodoxime proxetil.
    Fukutsu N; Kawasaki T; Saito K; Nakazawa H
    J Chromatogr A; 2006 Oct; 1129(2):153-9. PubMed ID: 16846608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification, isolation and characterization of potential degradation products in pioglitazone hydrochloride drug substance.
    Ramulu K; Kumar TT; Krishna SR; Vasudev R; Kaviraj M; Rao BM; Rao NS
    Pharmazie; 2010 Mar; 65(3):162-8. PubMed ID: 20383934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of HPLC/MS, GC/MS, NMR, UV and IR to identify a degradation product of eperisone hydrochloride in the tablets.
    Ding L; Wang X; Yang Z; Chen Y
    J Pharm Biomed Anal; 2008 Jan; 46(2):282-7. PubMed ID: 18023316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improving the detection of degradants and impurities in pharmaceutical drug products by applying mass spectral and chromatographic searching.
    Freed AL; Kale U; Ando H; Rossi DT; Kingsmill CA
    J Pharm Biomed Anal; 2004 Jun; 35(4):727-38. PubMed ID: 15193717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of liquid chromatography-mass spectrometry for the identification of drug degradation products in pharmaceutical formulations.
    Wu Y
    Biomed Chromatogr; 2000 Oct; 14(6):384-96. PubMed ID: 11002276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isolation and characterization of process related impurities and degradation products of bicalutamide and development of RP-HPLC method for impurity profile study.
    Nageswara Rao R; Narasa Raju A; Narsimha R
    J Pharm Biomed Anal; 2008 Feb; 46(3):505-19. PubMed ID: 18162355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural identification and characterization of potential degradants of zotarolimus on zotarolimus-coated drug-eluting stents.
    Chen Q; Zielinski D; Chen J; Nowak S; Zhou CC
    J Pharm Biomed Anal; 2009 Dec; 50(5):778-86. PubMed ID: 19581067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.